| Khushwinder S Garcha Md, Inc | |
|
8706 Maple Hollow Ct Granite Bay CA 95746-6158 | |
| (716) 803-5991 | |
| (573) 250-7113 |
| Full Name | Khushwinder S Garcha Md, Inc |
|---|---|
| Speciality | Internal Medicine |
| Location | 8706 Maple Hollow Ct, Granite Bay, California |
| Authorized Official Name and Position | Khushwinder Garcha (PRESIDENT) |
| Authorized Official Contact | 7168035991 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Khushwinder S Garcha Md, Inc Po Box 2997 Granite Bay CA 95746-2997 Ph: (716) 803-5991 | Khushwinder S Garcha Md, Inc 8706 Maple Hollow Ct Granite Bay CA 95746-6158 Ph: (716) 803-5991 |
| NPI Number | 1447740832 |
|---|---|
| Provider Enumeration Date | 05/11/2018 |
| Last Update Date | 05/12/2018 |
| Medicare PECOS PAC ID | 5799024683 |
|---|---|
| Medicare Enrollment ID | O20190312001459 |
News Archive
Beckman Coulter Life Sciences continues its collaboration with one of the nation's leading Industry/University Cooperative Research Centers.
SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc. and a market leader for in vitro diagnostic assay components, is pleased to announce it will launch BioFX TMB Extended Range HRP Microwell Substrate (TMBX) at the American Association for Clinical Chemistry show in Los Angeles, CA from July 17-19, 2012.
A World Health Organization (WHO) and Republic of Korea project to improve the health of women and children in the Democratic People's Republic of Korea (DPRK) continues into its second year. The US$ 20 million project, funded by the Republic of Korea, will benefit five million people in the DPR Korea.
Ranbaxy Laboratories Limited (RLL), announced today that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valganciclovir Hydrochloride Tablets, 450 mg. Total annual market sales for Valganciclovir HCl Tablets were $239 million (IMS - MAT: March 2008).
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447740832 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | (* (Not Available)) | Primary |
| Provider Name | Khushwinder S Garcha |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1417120783 PECOS PAC ID: 9335295518 Enrollment ID: I20140717002488 |
News Archive
Beckman Coulter Life Sciences continues its collaboration with one of the nation's leading Industry/University Cooperative Research Centers.
SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc. and a market leader for in vitro diagnostic assay components, is pleased to announce it will launch BioFX TMB Extended Range HRP Microwell Substrate (TMBX) at the American Association for Clinical Chemistry show in Los Angeles, CA from July 17-19, 2012.
A World Health Organization (WHO) and Republic of Korea project to improve the health of women and children in the Democratic People's Republic of Korea (DPRK) continues into its second year. The US$ 20 million project, funded by the Republic of Korea, will benefit five million people in the DPR Korea.
Ranbaxy Laboratories Limited (RLL), announced today that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valganciclovir Hydrochloride Tablets, 450 mg. Total annual market sales for Valganciclovir HCl Tablets were $239 million (IMS - MAT: March 2008).
› Verified 3 days ago
News Archive
Beckman Coulter Life Sciences continues its collaboration with one of the nation's leading Industry/University Cooperative Research Centers.
SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc. and a market leader for in vitro diagnostic assay components, is pleased to announce it will launch BioFX TMB Extended Range HRP Microwell Substrate (TMBX) at the American Association for Clinical Chemistry show in Los Angeles, CA from July 17-19, 2012.
A World Health Organization (WHO) and Republic of Korea project to improve the health of women and children in the Democratic People's Republic of Korea (DPRK) continues into its second year. The US$ 20 million project, funded by the Republic of Korea, will benefit five million people in the DPR Korea.
Ranbaxy Laboratories Limited (RLL), announced today that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valganciclovir Hydrochloride Tablets, 450 mg. Total annual market sales for Valganciclovir HCl Tablets were $239 million (IMS - MAT: March 2008).
› Verified 3 days ago
Margaret K. Smith Chiropractic, Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 8700 Auburn Folsom Rd Ste 300, Granite Bay, CA 95746 Phone: 619-804-6147 |